secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0001193125-24-152323
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Lifesciences sells Critical Care unit to BD for $4.2B cash, ends spin-off
--------------------------------------------------------------------------------

- All-cash sale of Critical Care product group to BD (NYSE: BDX) valued at $4.2 billion.
- Edwards will no longer pursue the previously announced spin-off of Critical Care.
- Transaction expected to close by end of 2024; impact to 2024 adjusted EPS immaterial.
- Critical Care will remain in Irvine, CA, led by current corporate VP Katie Szyman.
- After-tax cash proceeds to fund strategic structural heart innovation investments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000119312524152323/0001193125-24-152323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000119312524152323/d836710d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-152323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer